Ammoxetine hydrochloride enteric-coated tablets
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
DepressionHealthy ParticipantsMajor Depressive Disorder (MDD)Participants With Mild Hepatic ImpairmentParticipants With Moderate Hepatic ImpairmentParticipants With Moderate Renal Impairment
Phase 1
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
CompletedNCT03456388
Start: 2017-10-30End: 2019-02-15Updated: 2019-02-20
Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject
NCT03850834
Start: 2019-03-10End: 2019-10-31Target: 36Updated: 2019-02-22
Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets
CompletedNCT07508501
Start: 2023-02-08End: 2023-04-04Updated: 2026-04-02
A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
CompletedNCT07508462
Start: 2024-05-30End: 2024-08-02Updated: 2026-04-02
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
RecruitingNCT07694843
Start: 2026-03-30End: 2026-11-30Target: 24Updated: 2026-07-10
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
RecruitingNCT07694869
Start: 2026-05-10End: 2026-11-11Target: 16Updated: 2026-07-10